Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...
20h
TipRanks on MSNGossamer Bio Reports 2024 Financial Results and ProgressGossamer Bio ( ($GOSS) ) has released its Q4 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Gossamer ...
EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0MLight Up your Portfolio with Spark:Easily identify stocks' risks and ...
Cash, cash equivalents and marketable securities as of December 31, 2024, were $294.5 million. As a result, we expect our ...
As the U.S. stock market faces a sell-off driven by concerns over tariffs and economic uncertainty, investors are increasingly looking for opportunities that can offer resilience and potential growth.
Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Thursday reported a loss of $33 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...
SAN DIEGO - Gossamer Bio, Inc. (NASDAQ: GOSS) saw its shares climb 5.4% after the biopharmaceutical company reported better-than-expected fourth quarter results and provided updates on its pulmonary ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
2d
Zacks Investment Research on MSNGossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue EstimatesGossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results